PAVmed Inc. Reports Modest Revenue Growth and Significant Operating Losses in Q2 2026

PAVmed Inc. reported its financial results for the second quarter of 2026, revealing a modest revenue of $33,000 for the three months ended June 30, compared to $6,000 in the same period last year. For the first half of 2026, the company generated $55,000 in revenue, up from $14,000 in the first half of 2025. Despite this increase, PAVmed continues to face significant operating losses, with a net loss attributable to common stockholders of $5.5 million for the second quarter, an improvement from a loss of $11.9 million in the prior year. The company’s total operating expenses rose to $7.1 million in the second quarter, up from $4.7 million a year earlier, primarily driven by increased research and development costs.

The company’s balance sheet as of June 30, 2026, showed total assets of $40.2 million, a slight increase from $38.8 million at the end of 2025. Current assets increased significantly to $4.9 million, primarily due to a rise in cash reserves, which reached $3.8 million, compared to $1.5 million at the end of 2025. PAVmed's total liabilities decreased to $20.9 million from $16.5 million, largely due to the refinancing of its Senior Secured Convertible Notes. The company’s stockholders’ equity also improved, totaling $19.3 million, up from $22.3 million at the end of the previous fiscal year.

Strategically, PAVmed has made significant moves, including the issuance of 30,000 shares of Series D Convertible Preferred Stock, raising approximately $30 million in February 2026. This capital was used to redeem all outstanding Series C Preferred Stock and refinance existing debt. The company also appointed Joseph Virgilio as Chief Business Officer for Medical Devices, aiming to enhance its medical device portfolio, which includes the PortIO implantable intraosseous vascular access device and a newly licensed endoscopic imaging technology from Duke University.

Operationally, PAVmed continues to focus on expanding its market presence, particularly through its subsidiaries. Lucid Diagnostics, which markets the EsoGuard Esophageal DNA Test, has secured a contract with the U.S. Department of Veterans Affairs to provide esophageal precancer testing, potentially increasing its customer base significantly. The company is also pursuing strategic partnerships to enhance the adoption of its Veris Cancer Care Platform. However, PAVmed acknowledges ongoing challenges, including the need to control operating costs and generate substantial revenue growth to ensure its long-term viability.

Looking ahead, PAVmed anticipates continued losses and negative cash flows from operations. The company plans to fund its operations through a combination of debt and equity financing, while also aiming to increase revenues from its Veris Cancer Care platform. The management has expressed concerns about its ability to meet financial obligations within the next year, emphasizing the need for effective cost management and successful capital raising efforts to sustain operations.